得力生注射液联合肝动脉化疗栓塞治疗原发性肝癌的临床研究

目的评价得力生注射液联合经肝动脉化疗栓塞术(transcatheterarterialchemoembolization,TACE)治疗原发性肝癌(hepatocelluarcarcinoma,HCC)患者的临床效果及不良反应。方法选择无手术指征的HCC患者62例,随机分为试验组(得力生联合TACE)32例和对照组(单纯TACE)30例,选用FAP肝动脉化疗方案,试验组加用得力生注射液50ml/d静滴,15d~20d。治疗2个周期后观测患者的近期疗效、细胞免疫功能、生活质量及不良反应。结果试验组有效率为56.3%(18/32),对照组为43.3%(13/30),两组之间差异无统计学意义,(P>0.05)。试验组较对照组生活质量(KPS评分)明显提高,(P<0.05)。试验组细胞免疫功能提高,其中NK细胞升高明显,差异有统计学意义,(P<0.05)。试验组化疗毒副反应减轻,与对照组比较无统计学意义,(P>0.05)。结论得力生注射液联合TACE治疗能提高HCC患生存质量,增强患者的细胞免疫功能。

Clinical study of Delisheng injection combined with transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma

Objective:To evaluate the therapeutic effect , the cell immunity, quality of life , side effect of Delisheng injection combined with transcatheter arterial chemoembolization(TACE) in treatment for human primary hepatocelluar carcinoma(HCC). Methods:Sixty two cases with primary HCC were randomly divided into two groups. The treated group (n=32) received Delisheng injection combined with TACE , and the control group (n=30)were treated with TACE alone. Results: The response rates in the treated group and control group were 56.3 % and 43. 3 %, respectively, with no significant difference , P>0.05. There were significant differences in the raise of Karnofsky score ( KPS ) and NK cells between the treated group and control group , P<0.05.Conclusion :The treatment of Delisheng injection combined with TACE is helpful to improve the cell immunity and quality of life for patients with HCC.